Form 4: RAPT Therapeutics Acquired by GSK Subsidiary

RAPT Therapeutics, Inc. director Ashley L. Dombkowski reports changes in beneficial ownership following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.

Summary

• RAPT Therapeutics, Inc. was acquired by GlaxoSmithKline LLC (Parent) through its wholly owned subsidiary Redrose Acquisition Co. (Purchaser).
• The acquisition was completed via a tender offer at $58.00 per share in cash, without interest and subject to applicable withholding taxes, followed by a merger on March 3, 2026.
• Ashley L. Dombkowski, a director of RAPT Therapeutics, reported changes in beneficial ownership due to the completion of this merger.
• Outstanding Restricted Stock Units (RSUs) were cancelled and converted into the right to receive cash equal to the total number of shares issuable multiplied by the $58.00 Offer Price.
• Outstanding stock options with an exercise price less than $58.00 were accelerated, fully vested, and converted into the right to receive cash equal to the total number of shares subject to the option multiplied by the difference between the Offer Price and the exercise price.
• Dombkowski's 4,956 Common Stock RSUs and 25,000 Director Stock Options (with a $7.44 exercise price) were subject to these conversion terms.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive event for RAPT Therapeutics shareholders, who received a significant cash premium for their shares and equity awards, indicating a successful exit for the company's investors.

Positives

• RAPT Therapeutics shareholders received a cash payment of $58.00 per share, representing a premium over the pre-announcement trading price.
• Equity awards, including Restricted Stock Units and stock options held by directors and employees, were converted into cash, providing liquidity and value realization.
• Stock options were accelerated and fully vested immediately prior to the merger, benefiting option holders by allowing them to cash out their awards.

Negatives

• RAPT Therapeutics ceases to be an independent publicly traded company, removing its stock from public markets.
• Long-term growth potential as an independent entity is no longer available to previous shareholders.

Risks

• The filing is a post-merger report and does not detail new or ongoing risks for RAPT Therapeutics as an independent entity, as it has been acquired. Risks related to the merger transaction itself (e.g., regulatory approvals, financing) would have been relevant prior to the merger's completion.

Future Outlook

The filing primarily reports a completed transaction, the acquisition of RAPT Therapeutics by GlaxoSmithKline LLC. As RAPT Therapeutics is now an indirect wholly owned subsidiary, its future outlook will be integrated within GlaxoSmithKline's broader strategic plans and financial reporting.

Management Comments

• The filing is a standard Form 4 reporting a completed transaction and does not contain direct quotes or paraphrased statements from company management regarding future strategy or performance, beyond the factual reporting of the merger agreement terms.

Industry Context

StockSavvy.ai notes that the acquisition of RAPT Therapeutics by GlaxoSmithKline LLC reflects a continuing trend of larger pharmaceutical companies acquiring smaller biotechnology firms to bolster their pipelines and intellectual property. This strategy allows established players to gain access to innovative therapies and research without the inherent risks and lengthy development cycles of internal R&D, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• StockSavvy.ai observes that the $58.00 per share cash offer for RAPT Therapeutics is consistent with industry benchmarks for biotech acquisitions, often involving significant premiums over pre-announcement trading prices.
• Similar acquisitions, such as Pfizer's acquisition of Seagen for $43 billion (approximately $229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion (approximately $200 per share), demonstrate the willingness of large pharma to pay substantial premiums for promising assets.
• The acceleration and cash-out of equity awards for RAPT's directors and employees also align with standard practices in such transactions, ensuring smooth integration and incentivizing key personnel.

Management Changes

Corporate Governance

Legal Proceedings

• The filing does not mention any ongoing litigation or regulatory matters.

Related Party Transactions

• The filing does not disclose any related party dealings beyond the acquisition itself, which involves the reporting person as a director of the acquired entity.

Stakeholder Impact

• Shareholders: Received $58.00 per share in cash for their common stock, realizing immediate value.
• Equity Award Holders (including directors): Restricted Stock Units and stock options were converted into cash, providing liquidity and value.
• Employees: While not explicitly detailed, employees with equity awards would have benefited from the cash conversion. The company's integration into GSK could lead to changes in employment structure.
• Customers/Suppliers: Potential changes in relationships as RAPT becomes part of a larger organization, but no direct impact is detailed in this filing.

Next Steps

• As RAPT Therapeutics is now an indirect wholly owned subsidiary of GlaxoSmithKline LLC, its operations and strategic direction will be integrated into the parent company. No specific future actions for RAPT as an independent entity are mentioned.

Key Dates

Keywords

RAPT Therapeutics, GlaxoSmithKline, GSK, Merger, Acquisition, Tender Offer, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Biotechnology, Pharmaceuticals